Commentary on the Association of Symptoms Associated With Gadolinium Exposure/Gadolinium Deposition Disease and Gadolinium-Based Contrast Agents-Reference-Cited by-同舟云学术

Commentary on the Association of Symptoms Associated With Gadolinium Exposure/Gadolinium Deposition Disease and Gadolinium-Based Contrast Agents

Published:2022-05-05 Issue:10 Volume:57 Page:674-676
ISSN:1536-0210
Container-title:Investigative Radiology
language:en
Short-container-title:Invest Radiol

Author:

Semelka Richard C.,Ramalho Miguel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference17 articles.

1. Use of real-life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure;Invest Radiol,2022

2. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis;JAMA Intern Med,2020

3. Current and future MR contrast agents: seeking a better chemical stability and Relaxivity for optimal safety and efficacy;Invest Radiol,2020

4. Gadolinium retention as a safety signal: experience of a manufacturer;Invest Radiol,2020

5. Acute adverse events after gadolinium-based contrast agent administration;Radiology,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A New Era in Magnetic Resonance Contrast Media;Investigative Radiology;2023-10-20

2. Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination;Investigative Radiology;2023-10-13

3. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses;Investigative Radiology;2023-04-22